Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.īlueprint Medicines doesn't appear a compelling earnings-beat candidate. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Over the last four quarters, the company has beaten consensus EPS estimates two times.Īn earnings beat or miss may not be the sole basis for a stock moving higher or lower. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.įor the last reported quarter, it was expected that Blueprint Medicines would post a loss of $2.73 per share when it actually produced a loss of $2.65, delivering a surprise of +2.93%. So, this combination makes it difficult to conclusively predict that Blueprint Medicines will beat the consensus EPS estimate.ĭoes Earnings Surprise History Hold Any Clue?Īnalysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. On the other hand, the stock currently carries a Zacks Rank of #3. This has resulted in an Earnings ESP of -0.03%. How Have the Numbers Shaped Up for Blueprint Medicines?įor Blueprint Medicines, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). Please note that a negative Earnings ESP reading is not indicative of an earnings miss. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. Our proprietary surprise prediction model - the Zacks Earnings ESP (Expected Surprise Prediction) - has this insight at its core. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.Įstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
The consensus EPS estimate for the quarter has been revised 1.25% lower over the last 30 days to the current level. Revenues are expected to be $42.71 million, down 31.9% from the year-ago quarter. This cancer drug developer is expected to post quarterly loss of $2.66 per share in its upcoming report, which represents a year-over-year change of -48.6%.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. On the other hand, if they miss, the stock may move lower. The earnings report, which is expected to be released on May 4, 2023, might help the stock move higher if these key numbers are better than expectations. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. Blueprint Medicines (BPMC) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023.
0 kommentar(er)
